中国化学(601117) - 2024 Q3 - 季度财报

Financial Performance - The operating revenue for Q3 2024 was CNY 43,543,307,080.83, representing an increase of 8.57% compared to the same period last year[1]. - The net profit attributable to shareholders for Q3 2024 was CNY 998,722,879.62, reflecting a growth of 28.57% year-on-year[1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 830,517,738.11, up by 9.42% from the previous year[1]. - In the first three quarters of 2024, the company achieved operating revenue of CNY 134.15 billion, with a net profit attributable to shareholders of CNY 3.84 billion[9]. - Total operating revenue for the first three quarters of 2024 reached ¥134.74 billion, an increase from ¥131.66 billion in the same period of 2023, representing a growth of approximately 2.4%[14]. - Net profit for the first three quarters of 2024 was ¥4.21 billion, compared to ¥4.03 billion in 2023, reflecting an increase of about 4.3%[15]. - The operating profit for the first three quarters of 2024 was ¥5.06 billion, up from ¥4.66 billion in the previous year, indicating a growth of about 8.4%[15]. - The total comprehensive income for the first three quarters of 2024 was ¥4.20 billion, compared to ¥4.08 billion in 2023, representing a growth of about 2.9%[17]. Assets and Liabilities - The total assets at the end of Q3 2024 amounted to CNY 224,672,311,681.06, an increase of 2.54% compared to the end of the previous year[2]. - The equity attributable to shareholders increased to CNY 60,475,842,960.31, marking a growth of 5.18% year-on-year[2]. - The company's total liabilities amounted to ¥157.16 billion, up from ¥155.04 billion year-over-year, indicating a growth of approximately 1.4%[12]. - The company's total non-current liabilities decreased to ¥9.90 billion from ¥11.50 billion year-over-year, a reduction of approximately 13.9%[12]. - The company's retained earnings increased to ¥36.33 billion from ¥33.58 billion, reflecting a growth of about 8.2%[12]. Cash Flow - The net cash flow from operating activities for the year-to-date was negative CNY 5,631,766,446.69, indicating a decline due to reduced interbank lending by the financial company[4]. - In the first three quarters of 2024, the cash inflow from operating activities was CNY 126.68 billion, an increase of 8.5% compared to CNY 116.43 billion in the same period of 2023[18]. - The net cash outflow from operating activities was CNY -5.63 billion, worsening from CNY -3.37 billion year-on-year[18]. - The cash inflow from investment activities totaled CNY 2.81 billion, up from CNY 2.49 billion in the previous year[19]. - The net cash outflow from investment activities was CNY -1.25 billion, an improvement from CNY -3.21 billion in the same period of 2023[19]. - The cash inflow from financing activities was CNY 2.71 billion, down from CNY 4.80 billion year-on-year[19]. - The net cash outflow from financing activities was CNY -2.74 billion, compared to a net inflow of CNY 1.74 billion in the previous year[19]. - The total cash and cash equivalents at the end of the period stood at CNY 33.39 billion, an increase from CNY 31.43 billion at the end of the same period last year[19]. Shareholder Information - The company had a total of 109,614 common shareholders at the end of the reporting period[6]. - Basic earnings per share for Q3 2024 were CNY 0.17, up 30.77% compared to the same period last year[1]. - The company reported a basic earnings per share of ¥0.63 for the first three quarters of 2024, compared to ¥0.61 in 2023, reflecting an increase of approximately 3.3%[17]. Operational Highlights - The total value of new contracts signed reached CNY 284.08 billion, with domestic contracts accounting for CNY 218.37 billion and overseas contracts for CNY 65.71 billion[9]. - The company maintained a strong focus on high-quality development and has made positive progress in various operational areas during the reporting period[9]. - The company is committed to new product and technology development, although specific details were not disclosed in the report[9]. - Research and development expenses for the first three quarters of 2024 were ¥4.08 billion, compared to ¥3.91 billion in 2023, marking an increase of approximately 4.4%[14]. Inventory and Receivables - Accounts receivable increased to CNY 35.50 billion, up from CNY 26.25 billion at the end of 2023, indicating a rise in credit sales[10]. - Inventory levels rose to CNY 7.18 billion, compared to CNY 5.51 billion at the end of 2023, reflecting increased production or stockpiling[10].